Fulvestrant Injection 250mg/5ml

Fulviglen 250mg Injection contains the active constituent fulvestrant. It is used in the treatment of estrogen receptor-positive metastatic breast cancer in postmenopausal women. It is also used in combination with Palbo-ciclib in the treatment of hormone receptor-positive, and human epidermal growth factor 2-negative breast cancer (metastatic). It is not recommended in patients with chronic liver problems.

Talk to your doctor if you have bleeding disorders, bone diseases, alcoholism, liver or kidney problems. It is not recommended for adolescents and children under 18 years of age. Use effective birth control during the treatment and for at least 2 years after the last dose. Inform your doctor if you experience any allergic reactions such as swelling of the face, lips, tongue or throat while being treated with Fulviglen 250mg Injection.